Lyell Immunopharma, Inc. (LYEL) Technical Analysis & Indicators

Lyell Immunopharma, Inc. (LYEL) — Price $10.78 HealthcareBiotechnology — NASDAQ

Latest reported results:

Technical analysis of Lyell Immunopharma, Inc. (LYEL): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial,...

Price Performance

1 month-31.73%
3 months-15.38%
Year-to-date-64.98%
1 year-12.43%
3 years-66.73%
5 years-95.44%

52-Week Range

52-week High$45.00
52-week Low$10.46
Avg Volume (90d)159K

Technical Indicators

SMA 50$13.82
SMA 200$20.01
Beta-0.07
30-day Volatility (annualised)69.7%
Price vs SMA 50-22.0%
Price vs SMA 200-46.1%

Monthly Close (12 months)

MonthCloseChange
2025-10$16.66
2025-11$24.00+44.1%
2025-12$30.78+28.3%
2026-01$24.00-22.0%
2026-02$24.00+0.0%
2026-03$20.06-16.4%
2026-04$19.73-1.6%
2026-05$17.33-12.2%
2026-06$14.05-18.9%
2026-07$12.94-7.9%
2026-08$14.32+10.7%
2026-09$10.78-24.7%

Upcoming Earnings

DateEPS Est.Revenue Est.
2026-09-14$-2.53
2026-09-14$159M
2026-09-14$-0.26$14M
2026-09-14
2026-09-14$0.84$26M
2026-09-14

Price

Price$10.78
Market Cap$264M
ExchangeNASDAQ
CountryUS

Valuation Ratios

Price / Book0.90
EV / EBITDA-1.08
Dividend Yield0.00%

Financial Health

Debt / Equity0.16
Current Ratio5.36
Piotroski F-Score2
Altman Z-Score-4.46

Related companies: ACIU · ALDX · ALLO · AMRN · CABA · EDIT · GNLX

Explore sector: Healthcare · Biotechnology

More sections of LYEL: Overview · Financials · Valuation · Statistics · Estimates · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks